Abstract
Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Current Pharmaceutical Design
Title: Tissue Transport of Anti-cancer Drugs
Volume: 8 Issue: 22
Author(s): Jan Lankelma
Affiliation:
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Abstract: Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Export Options
About this article
Cite this article as:
Lankelma Jan, Tissue Transport of Anti-cancer Drugs, Current Pharmaceutical Design 2002; 8 (22) . https://dx.doi.org/10.2174/1381612023393512
DOI https://dx.doi.org/10.2174/1381612023393512 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lanthanum, Gallium and their Impact on Oxidative Stress
Current Medicinal Chemistry Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Current Cancer Drug Targets Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Proteomics in Computer-Aided Drug Design
Current Computer-Aided Drug Design Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued) Development of A Novel System Based on Green Magnetic / Graphene Oxide / Chitosan /Allium Sativum / Quercus / Nanocomposite for Targeted Release of Doxorubicin Anti-Cancer Drug
Anti-Cancer Agents in Medicinal Chemistry Dendritic Cells and the Promise of Therapeutic Vaccines for Human Immunodeficiency Virus (HIV)-1
Current HIV Research Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Lupus Nephritis: A Treatment Update
Current Clinical Pharmacology Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways
Anti-Cancer Agents in Medicinal Chemistry Role of Pentacyclic Triterpenoid Acids in the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry